Syngene International
SYNGENE · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar Shaw · MD: Jonathan Hunt · Listing date: Aug. 11, 2015 · Employees: 5437 · Bangalore · http://www.syngeneintl.com

Stock Price vs Company Growth
1d
0.1%
1w
6.0%
1m
16.3%
3m
37.4%
6m
39.1%
1y
40.8%
5y
5.8%
10y
7.7%
all
9.5%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 400 0.1%
381
678
Company Overview

Sales
3,720 Cr
Growth: 5.8%
Profit after Tax
352 Cr
Growth: -24.8%
Mid Cap
16,122 Cr
P/E: 45.7x
Industry P/E: 27.8x
Fundamentals

Sales (Cr) ₹ 3,720
Growth 5.8%
EBITDA 25.8%
P/S 4.3x
Dividend 0.2%
P/E 45.7x
Book Value ₹ 122
PEG Ratio 7.9x
ROE 7.3%
P/B 3.3x
Shareholding Pattern

Institutions
Government Pension Fund Global
1.14 %
Uti-Mid Cap Fund
1.03 %
Qualified Institutional Buyer
0.15 %
Promoters
Biocon Limited
70.1 %
Biocon Limited Employee Welfare Trust (Murali Krishnan K N And Amitava Saha)
0.32 %
Yamini R Mazumdar
0.01 %
Others
Increase    Decrease    No change
Company Profile Detailed

The company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide.
Investors (435)
Followers (15)